Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
Kelly R, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua A, Pook D, Baenziger O, Gibbs P, Tran B. Kelly R, et al. Among authors: weickhardt a. BJU Int. 2021 Oct;128 Suppl 1:18-26. doi: 10.1111/bju.15364. BJU Int. 2021. PMID: 34622543
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12. J Clin Oncol. 2012. PMID: 22412142 Clinical Trial.
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA, Willson K, Vincent AD, Tamjid B, Lee M, Bergin A, Gan C, Campbell A, Stewart J, Pezaro C, Tran B, Weickhardt AJ. Hamid AA, et al. Among authors: weickhardt aj. Asia Pac J Clin Oncol. 2018 Oct;14(5):e399-e404. doi: 10.1111/ajco.12840. Epub 2018 Jan 10. Asia Pac J Clin Oncol. 2018. PMID: 29318740
Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.
Vargas HA, Kramer GM, Scott AM, Weickhardt A, Meier AA, Parada N, Beattie BJ, Humm JL, Staton KD, Zanzonico PB, Lyashchenko SK, Lewis JS, Yaqub M, Sosa RE, van den Eertwegh AJ, Davis ID, Ackermann U, Pathmaraj K, Schuit RC, Windhorst AD, Chua S, Weber WA, Larson SM, Scher HI, Lammertsma AA, Hoekstra OS, Morris MJ. Vargas HA, et al. Among authors: weickhardt a. J Nucl Med. 2018 Oct;59(10):1516-1523. doi: 10.2967/jnumed.117.206490. Epub 2018 Apr 6. J Nucl Med. 2018. PMID: 29626121 Free PMC article. Clinical Trial.
Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.
Kramer GM, Yaqub M, Vargas HA, Schuit RC, Windhorst AD, van den Eertwegh AJM, van der Veldt AAM, Bergman AM, Burnazi EM, Lewis JS, Chua S, Staton KD, Beattie BJ, Humm JL, Davis ID, Weickhardt AJ, Scott AM, Morris MJ, Hoekstra OS, Lammertsma AA. Kramer GM, et al. Among authors: weickhardt aj. J Nucl Med. 2019 Sep;60(9):1221-1227. doi: 10.2967/jnumed.118.220111. Epub 2019 Mar 8. J Nucl Med. 2019. PMID: 30850488 Free PMC article.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
86 results